Dear Daniel, took a quick look in your paper and it looks fascinating : GRIDSS is among the first algorithms, that combines assembly, SR and PR analysis. Wondering how extensive have you tested it in on cancer samples, for somatic SV detection. We can also take the conversation via email, if you'd like. Thanks.
Dear all,
we have been sequencing pediatric tumors by using Illumina technology (normal-tumor pairs, paired end reads of 150nt each), and I have been using several SV callers (including DELLY, MANTA, LUMPY) in order to call the Structural Variants.
Considering the initial files of SV calls, what is the set of criteria you would recommend for filtering ? particularly, the number of PR (paired-end reads) or SR (split - reads) ? thank you,
-- bogdan
1 answer
This depends on the relative cost of false positives vs false negatives. What FDR and sensitivity are you aiming for?
I've done some fairly extensive benchmarking of SV callers for which you can find germ-line and simulation results at http://shiny.wehi.edu.au/cameron.d/sv_benchmark to given you some idea of the trade-off between FDR and sensitivity for various callers. The DREAM Somatic Mutation Calling Challenge results also give you a basic idea of these trade-offs.
In my somatic usage of GRIDSS, I've found that requiring assembly support has been a very effective filter - something that you could also do for manta. As for direct read support, the relative strength of RP and SR support depends on the library fragment size distribution and will be different for each library. For 2x150bp sequencing, you'll have weak RP support even for real variants in libraries with mean fragment size <300bp. Ideally, you would filter on variant quality directly, instead of RP and SR independently but not many SV callers actually report a variant quality score, and none that I know of report an even remotely calibrated quality score.
Disclaimer: I am the author of GRIDSS.
Log in to answer this question.